Story
α-Lipoic acid (ALA)
Last updated
In one pass α-Lipoic acid (ALA) is a small molecule your body makes for itself.
Educational content, not medical advice — consult a clinician.
Story path
Chapter 1
Soluble in both water and fat
α-Lipoic acid () is a small molecule your body makes for itself. It is not a vitamin, and you cannot run short of it. Its real job in the body is to serve as a part on several mitochondrial enzymes that burn sugar for energy; the antioxidant effect sold on supplement labels is only a side job.
What makes it unusual is that it dissolves in both water and fat. Most antioxidants can work only in the watery part of a cell or only in the fatty part; ALA can get into both.
Your cells make it all the time, so there is no such thing as falling ill from a lack of it. Food holds only micrograms of it, while one supplement capsule holds several hundred milligrams, an amount no diet could supply. Calling it an essential nutrient is supplement marketing. The identity that does hold up is a different one: in Germany, China and some other countries it is a prescription drug for diabetic peripheral neuropathy (nerve damage in the feet and hands from high blood sugar, felt as numbness and prickling), and the evidence that it eases those symptoms comes from randomized trials. The chapter on easing diabetic nerve symptoms covers it in detail.
The one urgent case is swallowing far more than a dose at once: seizures and deaths have been described in case reports. If someone has a seizure or becomes confused after that, go to the emergency department now.
What makes it unusual is that it dissolves in both water and fat. Most antioxidants can work only in the watery part of a cell or only in the fatty part; ALA can get into both.
Your cells make it all the time, so there is no such thing as falling ill from a lack of it. Food holds only micrograms of it, while one supplement capsule holds several hundred milligrams, an amount no diet could supply. Calling it an essential nutrient is supplement marketing. The identity that does hold up is a different one: in Germany, China and some other countries it is a prescription drug for diabetic peripheral neuropathy (nerve damage in the feet and hands from high blood sugar, felt as numbness and prickling), and the evidence that it eases those symptoms comes from randomized trials. The chapter on easing diabetic nerve symptoms covers it in detail.
The one urgent case is swallowing far more than a dose at once: seizures and deaths have been described in case reports. If someone has a seizure or becomes confused after that, go to the emergency department now.
Mechanism · Why it dissolves in both, and its sources
α-Lipoic acid (alpha-lipoic acid, ; also called thioctic acid) is an 8-carbon fatty acid carrying a ring closed by two sulfur atoms (a disulfide bond, -S-S-). Reed's laboratory first isolated it in 1951.Why it dissolves in both water and fat:
The 8-carbon fatty-acid backbone is oily, which lets it enter cell membranes.The disulfide bond and the carboxyl group lean toward water, which lets it stay in the cell's fluid.Dissolving in both is unusual among vitamins and antioxidants. Vitamin C dissolves only in water, vitamins E and A only in fat, and glutathione (GSH, the cell's main water-soluble antioxidant molecule) only in water; most antioxidants work on one side only.So it can reach the cell fluid, the cell membranes, the mitochondria and the nucleus at the same time.
Two mirror-image molecules (chirality):
The R form (R-ALA, dextrorotatory): the form found in nature, and the one the body makes and actually uses.The S form (S-ALA, levorotatory): a by-product of chemical synthesis, with weak biological activity.Most products on sale are racemic, meaning 50% R and 50% S, because industrial synthesis makes that cheaply.R-only products advertise the natural form, but pure R taken by mouth is unstable and tends to polymerize; salt forms such as the sodium salt (R-ALA-Na) are what make it stable.
How the body makes it:
Mitochondria build it themselves from octanoic acid (an 8-carbon fatty acid) plus sulfur.So it is not an essential nutrient: vitamins have to come from food, and ALA does not.Production may fall with aging or illness, which gives supplementation a little theoretical support; that step has not been shown in human trials.
How much is in food:
Red meat (organ meats): 5–30 µg/100 gSpinach, broccoli: about 5 µg/100 gYeast, tomato: trace amountsThe amounts in food are tiny; reaching a supplement dose (300–600 mg) from food is impossible.
So its identity is clear: a part the body makes and fixes onto metabolic enzymes, plus a treatment with one defined use (given by intravenous infusion for diabetic neuropathy). It is not the kind of molecule whose lack makes you ill.
Myth · Is pure R-ALA worth several times the price?
The most common chirality premium line in supplement marketing goes: the R form is natural, the S form is useless, so you must buy pure R. Let us check the evidence one point at a time.First, R really is the natural form and the biologically active one:
The α-lipoic acid () in mitochondria is the R form.The cofactor on pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase (KGDH), two of the sugar-burning enzymes, is also the R form.The S form can barely get into the active sites of these enzymes.
Second, once swallowed, stability becomes the problem:
Pure R tends to polymerize and dissolves poorly in water, so it is poorly absorbed and has low bioavailability.The racemic form (50% R and 50% S) is made by industrial synthesis and sits in the middle for stability.Stable forms such as the sodium salt (R-ALA-Na) solve the stability problem, but cost 5–10 times as much as racemic ALA.
Third, what the pharmacokinetic study says (a study of how blood levels of a drug change after a dose). In Carlson 2007 (*Altern Med Rev*), 12 healthy adults took the sodium salt of R-ALA by mouth. The salt resisted polymerizing, dissolved fully in water, and gave a higher peak blood level and a larger area under the concentration curve than ordinary R-ALA or racemic ALA. Two things to keep in mind: this was a 12-person study of blood levels, not a trial of whether it works; and the authors worked at a commercial research company (GeroNova Research). Whether higher blood levels buy a better clinical effect has never been tested head to head.
Fourth, the ALADIN series of randomized trials used racemic ALA:
The trials with the strongest evidence in diabetic neuropathy all used the racemic form, not R.Pure R has little clinical evidence of its own, mostly pharmacokinetic studies and small studies of metabolic markers.R is clinically stronger is not a conclusion from trials; it is marketing extrapolating from blood levels.
In practice:
If you are sure you want to take it and money is tight: racemic ALA, 300–600 mg, about $10–20 a month, is entirely reasonable.If you are willing to pay more for a theoretical advantage: R-ALA-Na, 100–300 mg, about $40–80 a month.Only buy R, never racemic has no evidence behind it: the trials with the strongest evidence in neuropathy used racemic ALA.
So the chirality premium mixes three things: a real commercial price gap, a little real pharmacokinetic data, and a great deal of marketing extrapolation. Following the ALADIN protocol with racemic ALA is the choice trials support; if you want to try R-ALA-Na on yourself, know that you are paying for a theoretical advantage, not for randomized-trial evidence.
Chapter 2
Its real job: helping burn sugar
The real job of α-lipoic acid () in the body is not antioxidant work. It is a part on enzymes inside mitochondria, the kind of part called a cofactor. This is the point marketing most often leaves out.
Mitochondria are the cell's power plants. ALA is fixed onto several of their enzymes and works like a swinging arm, passing the intermediates of sugar breakdown from one workstation to the next; without it, sugar cannot be burned any further. It handles some of the body's most important metabolic main lines: releasing energy from sugar, the citric-acid cycle (), processing branched-chain amino acids, and one-carbon metabolism.
Antioxidant work is its side job, and it is the part marketing inflates. Once swallowed, ALA is reduced to dihydrolipoic acid (DHLA), which can indeed clear free radicals and bind heavy metals. But this form never reaches high levels in the body and has a half-life of about 30 minutes, so it is a brief effect after a dose, not ongoing protection.
What this means for you:
The amount your body makes covers the real job; healthy people do not need extra for it.The antioxidant side job exists only briefly after a large dose.Selling its antioxidant effect as whole-body anti-aging is another version of the old vitamin E antioxidant megadose pitch.
Mitochondria are the cell's power plants. ALA is fixed onto several of their enzymes and works like a swinging arm, passing the intermediates of sugar breakdown from one workstation to the next; without it, sugar cannot be burned any further. It handles some of the body's most important metabolic main lines: releasing energy from sugar, the citric-acid cycle (), processing branched-chain amino acids, and one-carbon metabolism.
Antioxidant work is its side job, and it is the part marketing inflates. Once swallowed, ALA is reduced to dihydrolipoic acid (DHLA), which can indeed clear free radicals and bind heavy metals. But this form never reaches high levels in the body and has a half-life of about 30 minutes, so it is a brief effect after a dose, not ongoing protection.
What this means for you:
The amount your body makes covers the real job; healthy people do not need extra for it.The antioxidant side job exists only briefly after a large dose.Selling its antioxidant effect as whole-body anti-aging is another version of the old vitamin E antioxidant megadose pitch.
Evidence · Why the antioxidant network never paid off
The most-cited theoretical version of the antioxidant side job of α-lipoic acid () comes from a 1995 review by Packer. It says the reduced form, dihydrolipoic acid (DHLA), can help restore the spent states of other antioxidants such as vitamin C, vitamin E, glutathione and coenzyme , so ALA would be less a scavenger working in one place and more a hub in an antioxidant network.The idea is plausible as a mechanism, and it rests mainly on cell and animal experiments; it has never been confirmed on clinical endpoints in people. A pretty mechanism does not win a randomized trial, and the vitamin E antioxidant story is the cautionary tale.
Following that thread:
If it could really slow aging across the board, randomized trials should have shown it by now; yet no large trial has demonstrated it on such as lifespan, cardiovascular disease or cancer.Its real value lies in specific clinical uses, not in everyday wellness.
Mechanism · Why one enzyme needs five cofactors
α-Lipoic acid () and thiamin (vitamin B1) are the classic example of two cofactors on one enzyme.The pyruvate dehydrogenase complex (PDH) is the gate that sends pyruvate, the end product of glycolysis, into the mitochondria to be burned:
It is a huge complex of many subunits, about 9 MDa, built from 60–90 protein subunits.Its core is three kinds of subunit:E1: uses thiamin pyrophosphate (TPP, the active form of vitamin B1) as its cofactor to cut the carbon–carbon bond of pyruvate.E2 (dihydrolipoamide acetyltransferase): uses lipoamide, which is ALA bound covalently to the enzyme, as its cofactor to take over the acetyl group that was cut off.E3 (dihydrolipoyl dehydrogenase): uses FAD (the active form of riboflavin, vitamin B2) and (the active form of niacin, vitamin B3) to restore the used lipoamide.
The reaction, step by step:
1. Pyruvate enters E1 and is cut by TPP; the remaining two-carbon piece stays attached to TPP (as a hydroxyethyl group).
2. The lipoamide on E2 swings over, turns that piece into an acetyl group, and hands it to coenzyme A, making acetyl-CoA, which goes on into the citric-acid cycle.
3. After the handoff, the lipoamide is left in its reduced state. E3 uses FAD to return it to the oxidized state, and the electrons end up on NAD⁺ as NADH, the energy saved for making later on.
So one PDH reaction needs 5 cofactors present at the same time:
TPP (vitamin B1, thiamin)Lipoamide (α-lipoic acid)FAD (vitamin B2, riboflavin)NAD⁺ (vitamin B3, niacin)Coenzyme A (vitamin B5, pantothenic acid)
That is why thiamin, riboflavin, niacin, pantothenic acid and ALA all meet on this one enzyme. If any one of them runs short, PDH slows, pyruvate backs up at the exit of glycolysis, and lactate builds up.
α-Ketoglutarate dehydrogenase (KGDH) uses the same set of cofactors:
In the citric-acid cycle it handles the step that turns α-ketoglutarate into succinyl-CoA.It needs TPP, lipoamide, FAD, NAD⁺ and coenzyme A just the same.
What this means for the claim that taking ALA boosts energy metabolism:
The claim makes sense only when ALA is severely lacking, which is rare. By the mechanism, the ALA you swallow and the ALA already fixed onto the enzymes are two separate pools.Healthy people make enough of their own, and the hypothesis that topping up a cofactor tops up energy has almost no support in randomized human trials.If you want to look after energy metabolism, start with meals: vitamins B1, B2 and B3 and pantothenic acid all come from food, which makes far more sense than taking ALA on its own.
This points to something more general: energy metabolism is not missing X, take X; the whole production line runs together. That is often exactly why a single supplement does nothing.
Chapter 3
Easing diabetic nerve symptoms
α-Lipoic acid () has solid evidence in only one direction: easing the symptoms of diabetic peripheral neuropathy (DPN).
DPN feels like numb soles, a sense of walking on cotton wool, and pins-and-needles pain at night. High blood sugar slowly damages the nerve fibers (the axons), and oxidative stress is thought to be one of the routes. The nerves running from the spinal cord to the toes are the longest in the body, so the feet are always the first to be affected. By the mechanism, ALA, once reduced to dihydrolipoic acid (DHLA), can clear free radicals in the nerves and improve blood flow in the small vessels. What it relieves is the symptoms, not the cause.
Pooling four randomized double-blind trials of intravenous infusion, 600 mg a day for 3 weeks eased pain, burning and numbness much more than placebo did.
What it cannot do: there is no evidence that it makes damaged nerves grow back. It does not replace blood-sugar control, which remains the foundation of DPN treatment. And there is no trial evidence for using it to prevent DPN.
In practice:
Diagnosed DPN, blood sugar well controlled, symptoms still there: you can discuss with endocrinology or neurology an intravenous course of 600 mg a day for 3 weeks, or 600 mg a day by mouth long term (the evidence for oral maintenance is weaker than for the infusions).Diabetes with early abnormal sensations: control blood sugar first and use the first-line drugs for nerve pain, such as pregabalin and duloxetine; ALA is a reasonable add-on.
DPN feels like numb soles, a sense of walking on cotton wool, and pins-and-needles pain at night. High blood sugar slowly damages the nerve fibers (the axons), and oxidative stress is thought to be one of the routes. The nerves running from the spinal cord to the toes are the longest in the body, so the feet are always the first to be affected. By the mechanism, ALA, once reduced to dihydrolipoic acid (DHLA), can clear free radicals in the nerves and improve blood flow in the small vessels. What it relieves is the symptoms, not the cause.
Pooling four randomized double-blind trials of intravenous infusion, 600 mg a day for 3 weeks eased pain, burning and numbness much more than placebo did.
What it cannot do: there is no evidence that it makes damaged nerves grow back. It does not replace blood-sugar control, which remains the foundation of DPN treatment. And there is no trial evidence for using it to prevent DPN.
In practice:
Diagnosed DPN, blood sugar well controlled, symptoms still there: you can discuss with endocrinology or neurology an intravenous course of 600 mg a day for 3 weeks, or 600 mg a day by mouth long term (the evidence for oral maintenance is weaker than for the infusions).Diabetes with early abnormal sensations: control blood sugar first and use the first-line drugs for nerve pain, such as pregabalin and duloxetine; ALA is a reasonable add-on.
Evidence · What the ALADIN trials measured
Why is the evidence for this use so solid? Because a whole chain of (RCTs) holds it up. From the 1990s to 2006, the ALADIN series tested the same regimen again and again: intravenous α-lipoic acid (), 600 mg a day for 3 weeks.ALADIN I (Ziegler 1995): 328 people with type 2 diabetes and symptomatic peripheral neuropathy were randomized double-blind and treated by infusion for 3 weeks. The share whose symptom score improved by at least 30% was 82.5% on 600 mg and 57.6% on placebo; for about every 4 people treated, 1 more responded than on placebo (a , NNT, of about 4).Ziegler 2004 : it pooled four double-blind trials with the same design (600 mg a day by infusion for 3 weeks), namely ALADIN I, ALADIN III, SYDNEY and NATHAN II, 1,258 people in all. At 3 weeks the foot symptom score (the Total Symptom Score, TSS, which adds up pain, burning, abnormal sensations and numbness) improved 24.1% more than on placebo, and the share whose symptoms fell by at least half was 52.7% on treatment and 36.9% on placebo. Rates of side effects did not differ between the groups.ALADIN III gave infusions first and then oral maintenance: the foot TSS was not better than placebo (the infusion-then-oral group's foot TSS fell by −3.7, which was not superior to placebo).
Three things to remember when reading these numbers. They are 3-week symptom scores, not such as foot ulcers or amputations. These short trials cannot say how long the effect lasts after treatment stops. And the evidence for oral maintenance is weaker than for the infusions. For each trial's enrollment details and how oral and intravenous phases were sequenced, go to the original papers.
Clinical status (as of 2025): in Germany, Austria and central Europe, ALA (brand name Thioctacid) is a prescription drug and has been used for DPN for more than 50 years (approved in 1966). In the US it is still classed as an over-the-counter dietary supplement. China also has thioctic acid injection, a prescription drug for diabetic neuropathy.
Background · Why it is only a supplement in the US
The same molecule has been a prescription drug in Europe for 50 years and is still a supplement in the US. This is a story about how regulators differ.The German path:
1966: the German drug regulator approved α-lipoic acid (, brand name Thioctacid) for diabetic peripheral neuropathy (DPN), on the basis of early intravenous studies and clinical experience.1989–2006: the ALADIN and SYDNEY series of randomized trials strengthened the evidence.It is still a routine drug in German neurology and diabetes clinics today.
The US path:
The US Food and Drug Administration (FDA) has never formally approved it as a drug.Three explanations are commonly given. All are guesses, not an official account:No drug company ever submitted a complete New Drug Application (NDA) for it.Its patents expired long ago, so no one had a commercial reason to fund an expensive approval.The US market for nerve-pain drugs is held by pregabalin (Lyrica, Pfizer) and duloxetine (Cymbalta, Lilly), and an old, unpatented molecule would struggle to break in.The result: in the US it is still a supplement, and manufacturers cannot claim that it treats diabetic neuropathy.
What this shows:
Not approved by the FDA does not mean does not work. Whether a drug gets approved depends on business, regulation and clinical evidence together.The same molecule can be a drug in one country and a supplement in another, mostly because of patents, commercial incentives and regulatory preferences.In the US, some doctors do suggest it to patients with diabetic neuropathy, but insurance usually does not pay, and patients buy supplement-grade products out of pocket.
Similar molecules:
Coenzyme : a prescription drug for heart failure in Japan, a supplement in the US and Europe.N-acetylcysteine (): in the US it is both an FDA-approved prescription drug (the antidote for acetaminophen overdose) and a supplement on the shelf.
In practice:
When you judge a supplement, look at the evidence for the specific use, not just at whether the FDA approved it.Fifty years of prescription use in Germany, plus the four infusion trials Ziegler 2004 pooled, is stronger evidence than most US over-the-counter supplements have.But it is a drug for DPN, not a wellness product.
Chapter 4
How much weight does it take off?
α-Lipoic acid () melts fat is the other loud line in its marketing. The human data are sobering: on average, people lost only about 1.27 kg more than on placebo.
The mechanism sounds reasonable. In animals, ALA pushes an energy switch called , which turns fat synthesis down and fat burning up, and it also lowers appetite a little through the hypothalamus. So it was written into the fat loss and anti-metabolic-syndrome marketing story.
In people the effect shrinks. A pooling (Kucukgoncu 2017) found that people taking ALA lost about 1.27 kg more than those on placebo. The trials ran from 8 weeks to a year, so spread over each month the extra loss is only a few tenths of a kilogram.
So:
The fat-loss effect is real, but so small that the bathroom scale would barely show it.It cannot replace diet, exercise, or drugs where those are needed.ALA is a weight-loss drug takes a very small mechanistic signal and inflates it into a clinical selling point.
In fat loss it looks the same as in anti-aging: the mechanism makes sense, a small signal exists, the clinical meaning is weak, and the marketing runs far ahead of the evidence. If you have prediabetes or insulin resistance and your diet and exercise are already in place, it is a reasonable marginal thing to try. If you want it to stand in for lifestyle changes, or you expect noticeable weight loss, that road goes nowhere.
The mechanism sounds reasonable. In animals, ALA pushes an energy switch called , which turns fat synthesis down and fat burning up, and it also lowers appetite a little through the hypothalamus. So it was written into the fat loss and anti-metabolic-syndrome marketing story.
In people the effect shrinks. A pooling (Kucukgoncu 2017) found that people taking ALA lost about 1.27 kg more than those on placebo. The trials ran from 8 weeks to a year, so spread over each month the extra loss is only a few tenths of a kilogram.
So:
The fat-loss effect is real, but so small that the bathroom scale would barely show it.It cannot replace diet, exercise, or drugs where those are needed.ALA is a weight-loss drug takes a very small mechanistic signal and inflates it into a clinical selling point.
In fat loss it looks the same as in anti-aging: the mechanism makes sense, a small signal exists, the clinical meaning is weak, and the marketing runs far ahead of the evidence. If you have prediabetes or insulin resistance and your diet and exercise are already in place, it is a reasonable marginal thing to try. If you want it to stand in for lifestyle changes, or you expect noticeable weight loss, that road goes nowhere.
Numbers · How much weight people actually lost
The mechanistic case (still a hypothesis):It activates (the cell's energy sensor), which damps fat synthesis and promotes fat burning; animal models do show this.It improves insulin sensitivity, which could help fat loss indirectly.It suppresses AMPK in the hypothalamus and so suppresses appetite; this comes from a mouse study, Kim 2004 (*Nat Med*).These mechanisms carried α-lipoic acid () into the fat loss and anti-metabolic-syndrome market story.
The randomized trials in people (Kucukgoncu 2017, *Obes Rev*, a systematic review with ):
It included 11 randomized, double-blind, placebo-controlled studies (10 articles, 12 treatment arms): 534 people on ALA and 413 on placebo, most with metabolic syndrome, diabetes or obesity.Doses ran from 300 to 1800 mg a day, for 8 to 52 weeks.Weight: 1.27 kg more lost than on placebo (−1.27 kg, 95% −2.29 to −0.25; the confidence interval is the range the true effect most likely falls in).Body mass index (): 0.43 kg/m² lower.No link was seen between dose and weight lost, and results varied a lot from study to study.Only 3 of the studies also included a diet intervention.
Put another way:
1.27 kg more is spread over 8 to 52 weeks, so it comes to only a few tenths of a kilogram a month.The usual bar for a clinically meaningful loss is 5% or more of starting weight. For a 70 kg person that is 3.5 kg, far beyond what ALA delivers.Compare semaglutide 2.4 mg (the STEP 1 trial, 68 weeks): weight fell by about 15% (2.4% on placebo), roughly 1 kg a month.Compare simply eating 500 kcal a day less: 0.4–0.5 kg a week, or 3–4 kg over 8 weeks.
A later review of ALA in metabolic syndrome (2022) reached the same conclusion: promising as a mechanism, but high-quality trials are still needed to confirm any clinical effect.
Clinical · Where it ranks in metabolic syndrome
Where α-lipoic acid () really stands among the problems of metabolic syndrome and insulin resistance.The signals that show up (mostly from small, short trials):
Fasting insulin and the insulin-resistance index (): at 300–600 mg a day for 8–24 weeks, HOMA-IR improves slightly.Fasting glucose and (HbA1c, the average blood sugar of the past two to three months): a weak signal, and any change is small. and low-density lipoprotein (): small improvements in some studies.The inflammation marker C-reactive protein (): small falls in some studies.
What that means:
It has a real but small effect on insulin resistance, mostly on early markers of insulin sensitivity.It cannot replace:Weight loss (the first line for metabolic syndrome)Metformin (the first-line drug for type 2 diabetes) drugs (newer and effective, such as semaglutide and tirzepatide)Diet (a low glycemic index diet, the Mediterranean diet, the DASH diet)Exercise (strength training plus aerobic exercise)
A rough ranking of interventions for metabolic syndrome and insulin resistance, by evidence and effect (the certainty of the evidence in brackets: high / moderate / low / very low):
1. Diet change plus 5–10% weight loss (high, several randomized trials). In the DiRECT randomized trial, substantial weight loss put a sizable share of people recently diagnosed with type 2 diabetes into remission: off their glucose-lowering drugs, their blood sugar stayed below the diabetes line. Keep the distinction clear: remission and weight are , not such as heart attack, stroke or death.
2. Exercise: 150 minutes a week of moderate aerobic activity plus 2 strength sessions (high, guideline recommendation with consistent randomized trials).
3. Metformin: slows the move from prediabetes to type 2 diabetes (high, large randomized trials).
4. GLP-1 drugs such as semaglutide (high, large randomized trials in both obesity and diabetes).
5. Berberine (moderate, mainly small randomized trials).
6. N-acetylcysteine (), vitamin D, magnesium (moderate to low, depending on whether you are low to begin with).
7. ALA, 300–600 mg a day (low, small short trials with small effects): a marginal try once items 1–5 are in place.
8. Trimethylglycine (), creatine, protein: basic nutrition, not aimed at metabolic syndrome itself.
9. Everything else (very low).
In practice:
Metabolic syndrome, insulin resistance, prediabetes: items 1–3 are the core, and ALA ranks 7th.Diagnosed type 2 diabetes with peripheral neuropathy: its evidence suddenly gets much stronger, because that is a different use, easing the symptoms of neuropathy.Healthy people who want to prevent metabolic syndrome: you do not need it; spend the money on diet, exercise, sleep and weight.
So it is a textbook supplement-aisle case of clear mechanism, narrow clinical use, sprawling marketing, in the same group as NAC and curcumin. It has randomized-trial evidence for the symptoms of diabetic neuropathy and a small effect in metabolic syndrome; the anti-aging, weight-loss, antioxidant miracle claims go far beyond the evidence.
lean-2018-direct-lancet
Chapter 5
Who should take it, and how
In diabetic peripheral neuropathy, α-lipoic acid () is a molecule genuinely used as a drug; in the anti-aging and weight-loss stories on the shelf, it is marketing. Even in neuropathy, the first line is still blood-sugar-lowering drugs and drugs made for nerve pain, and ALA is at most an add-on.
Whether to take it depends less on the molecule than on your situation. Diagnosed neuropathy is worth discussing with a specialist; long-term use by healthy people has no hard-endpoint evidence.
Remember four safety points. It makes the body more sensitive to insulin, so taking it with glucose-lowering drugs means watching for low blood sugar and cutting the drug dose if needed. High doses may affect thyroid hormones, so people with Hashimoto's thyroiditis or Graves' disease should be careful. A few people develop insulin autoimmune syndrome (Hirata disease), with repeated low blood sugar: recurrent palpitations, cold sweats or shakiness after starting it mean stop it and get your blood sugar checked. Swallowing far more than a dose at once has caused seizures and deaths in case reports; if seizures or confusion follow, go to the emergency department now.
Whether to take it depends less on the molecule than on your situation. Diagnosed neuropathy is worth discussing with a specialist; long-term use by healthy people has no hard-endpoint evidence.
Remember four safety points. It makes the body more sensitive to insulin, so taking it with glucose-lowering drugs means watching for low blood sugar and cutting the drug dose if needed. High doses may affect thyroid hormones, so people with Hashimoto's thyroiditis or Graves' disease should be careful. A few people develop insulin autoimmune syndrome (Hirata disease), with repeated low blood sugar: recurrent palpitations, cold sweats or shakiness after starting it mean stop it and get your blood sugar checked. Swallowing far more than a dose at once has caused seizures and deaths in case reports; if seizures or confusion follow, go to the emergency department now.
In practice · Do you need it?
Do you need to take α-lipoic acid ()?Where it is recommended (high certainty, from several randomized trials):
1. Diagnosed diabetic peripheral neuropathy (DPN) with lasting symptoms: discuss with endocrinology or neurology an intravenous course of 600 mg a day for 3 weeks, or 600 mg a day by mouth long term (the evidence for oral maintenance is weaker than for the infusions).
2. Diabetes with early abnormal sensations (a risk sign for DPN) that keep progressing despite blood-sugar control and medication: ALA as an add-on (the first line is still pregabalin or duloxetine).
Where it is not recommended: healthy people taking it long term for anti-aging or antioxidant purposes, or hoping it will bring weight loss or prevent diabetes. None of these has hard-endpoint evidence, and the money does far more good spent on food, training and sleep. Neuropathy that is not caused by diabetes needs its cause found and treated first.
Safety and side effects:
Digestive upset: more common at high dosesRash or allergy: rareIt makes the body more sensitive to insulin, which brings a risk of low blood sugar: people with diabetes on glucose-lowering drugs must monitor their blood sugar and cut the drug dose if needed.Thyroid: high doses may affect the thyroid hormones and , so people with Hashimoto's thyroiditis or Graves' disease should be careful.Insulin autoimmune syndrome (Hirata disease): rare. The body makes antibodies against its own insulin, causing repeated low blood sugar when fasting or a few hours after meals. Gullo 2014 reported 6 Europeans taking 600 mg a day who developed it 30–120 days after starting, with fewer episodes once they stopped; the condition is tied to particular HLA types, and in Japan it is mostly triggered by sulfhydryl-containing drugs (Patel 2020 systematic review). Recurrent palpitations, cold sweats or shakiness mean stop it and get your blood sugar checked.Overdose (more than 10 g at once): seizures and deaths have been reported. These come from case reports, so how often it happens cannot be estimated. If seizures or confusion follow a dose far above normal, go to the emergency department now.
Overall, it is a textbook paradox molecule of the supplement aisle, a real clinical drug on one side and wall-to-wall marketing on the other. Within DPN it is a real drug; outside that use, anti-aging and weight loss are marketing. What decides whether it helps you is not the molecule but your particular situation.
In practice · Narrow uses, doses and forms
Where it may be worth considering (low certainty, from small or short trials):3. Metabolic syndrome, insulin resistance or prediabetes, with diet, exercise and weight management already in place and a wish to add one more thing: 300–600 mg a day for 8–24 weeks, watching how (an index of insulin resistance) and weight change.
4. Nerve damage caused by chemotherapy: the evidence is weak, but some cancer services will try it.
5. Fatty liver (metabolic dysfunction-associated steatotic liver disease, ) with metabolic syndrome: small randomized trials show a signal; discuss with hepatology and nutrition.
Dosing regimens:
Diabetic peripheral neuropathy (DPN), intensive phase: 600 mg a day by infusion for 3 weeksDPN maintenance: 600 mg a day by mouth, long termMetabolic syndrome or insulin resistance: 300–600 mg a dayWellness or general antioxidant use: no fixed dose is recommended, and no evidence supports it
Choosing a form:
Racemic α-lipoic acid (50% R and 50% S): the cheapest, about $10–20 a month, and what the ALADIN series used.R--Na (the sodium salt of the R form): more expensive, $40–80 a month; its blood levels are more stable, but the evidence that it works as well clinically is weak.R form as the free acid: unstable, not recommended.Multi-ingredient metabolic-support blends: unclear doses, and you pay a marketing premium.
Low priority or not recommended (very low certainty, or no evidence):
Healthy people taking it long term for anti-aging or antioxidant purposes: no hard-endpoint evidence; food, training and sleep give better value.Miracle weight loss: about 1.27 kg more than placebo, which means very little clinically.Preventing diabetes or DPN: no evidence for primary prevention.Neuropathy not caused by diabetes (vitamin B12 deficiency, alcohol, autoimmune disease): find the cause and treat it; ALA is no substitute.
Evidence · Next to other common supplements
Here is α-lipoic acid (ALA) set beside a few common supplements. High / moderate / low / very low in brackets is the certainty of the evidence for that use. In the table below, is N-acetylcysteine, DPN is diabetic peripheral neuropathy, is chronic obstructive pulmonary disease, OCD is obsessive-compulsive disorder, and and are the two omega-3 fatty acids in fish oil.| Dimension | ALA | NAC | Curcumin | Fish oil | Vitamin D |
|---|---|---|---|---|---|
| Mechanism | Clear (cofactor and antioxidant) | Clear | Clear | Clear | Clear |
| Main clinical use | DPN symptoms (high) | Acetaminophen poisoning (high) | Osteoarthritis, medium-high dose (moderate) | EPA and DHA to lower triglycerides (moderate to high) | Correcting deficiency (high) |
| Marginal uses | Metabolic syndrome (low); insulin resistance (low) | COPD (moderate); OCD (moderate) | Anti-inflammatory (moderate); depression (low) | General heart prevention (moderate to low) | General population (low) |
| Over-marketing | Weight loss, anti-aging | Anti-COVID | Cure-all anti-inflammatory | Heart miracle | Prevents everything |
| Real cost (per month) | $10–20 (racemic) | $10–15 | $15–30 (poorly absorbed) | $10–30 | $5–10 |
The shared pattern:
A clear mechanism, a narrow clinical use, and broad marketing.Effective within the real use; outside it, the certainty of the evidence is very low and what remains is marketing.Judging a supplement means looking at three things together: the molecule, the person, and the person's state.
Where ALA sits:
People with diabetic neuropathy: high certainty (several randomized trials), stronger than the great majority of supplements.People with metabolic syndrome or poor blood-sugar control: low certainty, an add-on ranked after diet, exercise and drugs.Healthy people wanting anti-aging or weight loss: very low certainty, not a priority.
It belongs to the same group as other supplement-grade drugs with clear uses:
NAC: acetaminophen poisoning (high), COPD (moderate), OCD (moderate)Curcumin: osteoarthritis and chronic inflammation (moderate), claims about cancer and anti-aging (very low)Omega-3 (EPA and DHA): high and some cardiovascular uses (moderate to high), general prevention (moderate to low): DPN (high), metabolic syndrome (low), anti-aging and weight loss (very low)
What the group has in common: a clear mechanism, strong randomized-trial evidence in one narrow use, and marketing that tries to push it onto a much wider audience.
A tool for you: whenever you see X cures everything marketing, drop X into this table. The default pattern you will usually find is strong evidence for a narrow use, very low evidence for the broad one.
References · 7
- Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R., & Hagen, T. M. (2009). Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochimica et Biophysica Acta, 1790(10), 1149-1160. 10.1016/j.bbagen.2009.07.026
- Packer, L., Witt, E. H., & Tritschler, H. J. (1995). Alpha-lipoic acid as a biological antioxidant. Free Radical Biology and Medicine, 19(2), 227-250. 10.1016/0891-5849(95)00017-R
- Ziegler, D., Nowak, H., Kempler, P., Vargha, P., & Low, P. A. (2004). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine, 21(2), 114-121. Pooled 4 trials of intravenous ALA 600 mg/day for 3 weeks (ALADIN I, ALADIN III, SYDNEY, NATHAN II), 1,258 patients (716 ALA, 542 placebo), from the manufacturer's (VIATRIS) database. Relative Total Symptom Score improvement 24.1% (13.5-33.4) and NIS-LL 16.0% in favour of ALA; responders (>= 50% TSS improvement) 52.7% vs 36.9%. These are intravenous, not oral, results (abstract, PMID 14984445). 10.1111/j.1464-5491.2004.01109.x
- Ziegler, D., Hanefeld, M., Ruhnau, K. J., et al. (1995). Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 38(12), 1425-1433. 328 patients with type 2 diabetes and symptomatic neuropathy; intravenous ALA 1,200, 600 or 100 mg or placebo for 3 weeks. Total symptom score fell 63.5% with 600 mg vs 38.4% with placebo; responders (>= 30% improvement) 82.5% with 600 mg vs 57.6% with placebo (p = 0.002). Adverse events 32.6% at 1,200 mg vs 18.2% at 600 mg and 20.7% on placebo (abstract, PMID 8786016). 10.1007/BF00400603
- Kucukgoncu, S., Zhou, E., Lucas, K. B., & Tek, C. (2017). Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. Obesity Reviews, 18(5), 594-601. Abstract: 10 articles; full text: 11 eligible studies with 12 treatment arms, 534 on ALA and 413 on placebo, 8-52 weeks, in varied populations (diabetes, metabolic syndrome, rheumatoid arthritis, NAFLD); only 3 studies were weight-loss interventions and 3 had a dietary component. ALA gave 1.27 kg (0.25-2.29) more weight loss and BMI -0.43 kg/m2 vs placebo. No waist outcome is reported (abstract, PMID 28295905; full text, PMC5523816). 10.1111/obr.12528
- Gullo, D., Evans, J. L., Sortino, G., Goldfine, I. D., & Vigneri, R. (2014). Insulin autoimmune syndrome (Hirata disease) in European Caucasians taking alpha-lipoic acid. Clinical Endocrinology, 81(2), 204-209. Case series: 'In Japanese individuals, IAS is associated with the human leucocyte antigen (HLA) HLA-DRB1*04:06 allele and often occurs upon exposure to sulphhydryl-containing compounds including LA.' Six Caucasian patients on lipoic acid 600 mg/day developed fasting and postabsorptive hypoglycaemia 30-120 days after starting it; stopping lipoic acid reduced the episodes. Five carried HLA-DRB1*04:03 and one DRB1*04:06 (abstract, PMID 24111525). 10.1111/cen.12334
- Patel, M., Shah, R., Ramteke-Jadhav, S., Patil, V., Patel, S. K., Lila, A., et al. (2020). Management of insulin autoimmune hypoglycaemia: single-centre experience from Western India with systematic review of world literature. Clinical Endocrinology, 92(5), 409-420. 7 Indian patients plus 294 patients from 149 publications. Antithyroid drugs were the most common triggers in Japanese patients and the most common HLA allele was DRB1*0406, while it was alpha-lipoic acid and HLA DRB1*0403 in non-Asians; sulfhydryl drugs were the most common triggers overall. 56% remitted with a complex-carbohydrate diet and trigger removal, 43% needed immunosuppressants, and 70% remitted within 6 months (abstract, PMID 32064669). 10.1111/cen.14174